Granted Patent B2

US 12,678,515 · App. 16/067,538 · Granted Jul 14, 2026

Inventors: Steven M. Ansell (Vancouver, CA); Xinyao Du (Richmond, CA)

Assignee: Acuitas Therapeutics, Inc.

A61K47/6929A61K31/7105A61K47/543C07C229/12

Abstract

Claims (19)

1 . A compound having the following structure (I):

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

L is, at each occurrence, ~O(C═O)—, wherein ~ represents a covalent bond to X;

X is CH;

Z is C 1 -C 6 alkyl wherein the C 1 -C 6 alkyl is substituted with C 1 -C 6 alkylaminyl;

R is, at each occurrence, H;

R 1 and R 2 independently have one of the following structures:

 and

a 1 and a 2 are, at each occurrence, independently an integer from 4 to 9.

2 . The compound of claim 1 , wherein the compound has the structures:

3 . The compound of claim 1 , wherein Z, has the structures:

4 . The compound of claim 1 , wherein Z-L has the structures:

5 . The compound of claim 1 , having the structures:

6 . A composition comprising the compound of claim 1 and a therapeutic agent.

7 . A method for administering a therapeutic agent to a patient in need thereof, the method comprising administering the composition of claim 6 to the patient.

8 . The composition of claim 6 , wherein the therapeutic agent is messenger RNA (mRNA).

9 . A lipid nanoparticle comprising the compound of claim 1 and a therapeutic agent.

10 . The lipid nanoparticle of claim 9 , wherein the therapeutic agent is messenger RNA (mRNA).

11 . The compound of claim 1 , wherein Z, has the structures:

Assignments (1)

Continuity (3)

References Cited (400)